SHCM
CELG

Sachem Head Capital Management’s Celgene Corp CELG Stock Holding History

Sachem Head Capital Management’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,650,000
Closed -$205M – 19
2017
Q1 		$205M Buy
1,650,000
+305,000
+23% +$36.5M 6.65% 2
2016
Q4 		$156M Buy
+1,345,000
New +$150M 5.96% 5

Other funds holding CELG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sachem Head Capital Management's CELG Position: Q2 2017 in Review

Sachem Head Capital Management sold out of Celgene Corp (CELG) in Q2 2017, closing a stake of 1,650,000 shares — an estimated $205M sold.

Sachem Head Capital Management first reported a position in CELG in Q4 2016 and held it in 2 quarters. The position peaked at $205M in Q1 2017. 1,428 funds tracked by Wall St. Rank hold CELG as of Q2 2017.

  • Sachem Head Capital Management reported no remaining Celgene Corp position as of Q2 2017 after selling out during the quarter.
  • Sachem Head Capital Management sold 1,650,000 Celgene Corp shares in Q2 2017, an estimated $205M.
  • Sachem Head Capital Management first reported a position in Celgene Corp in Q4 2016 and held it in 2 quarters.
  • Sachem Head Capital Management's Celgene Corp position peaked at $205M in Q1 2017.
  • 1,428 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2017.

Based on Sachem Head Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.